Abpro
Manufacturing · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
68 Cummings Park, Woburn, Massachusetts,...Phone Number
(800) 396-5890Website
www.abpro.coRevenue
<$5 MillionStock Symbol
ABPIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Abpro
Abpro Corporation is a clinical stage biotechnology company located in Woburn, Massachusetts. The Company's mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro's DiversImmuneTMplatform has been used successfully to generate monoclonal antibody therapies against 300 traditionally difficult targets. The DiversimmuneTM platform combines nano-immunology, next-generation sequencing, advanced engineering and bioinformatics to create monoclonal antibody therapies against traditionally difficult targets. The Company has a pipeline of therapies to treat cancer, eye, autoimmune, infectious diseases and other areas.Explore more
Abpro Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Abpro your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Abpro recently announced quarterly report
Check if Abpro has recently received funding, and reach out quickly before it becomes old news!
Check out if Abpro is spiking on competitors!
Website visits: Recent activity has been detected on your website
Click to see if Abpro had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Abpro has new funding data
Congratulate Masked Content for being promoted to Masked Content at Abpro
Product Launch: Get notified when Abpro launches new products
Abpro, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Abpro is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Abpro is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Abpro.
Abpro financials insights
Gather financial insights about Abpro, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Private Equity
$12.4M
Private Equity
$3.5M
2017
Private Equity
$10M
2020
Debt
$150K
Abpro Tech Stack
A closer look at the technologies used by Abpro
See more technologies
Most Recent Scoops
Partnership
Project
Partnership, Product Development, Product Management, Governmental Affairs & Regulation, Medical Research, Pharmaceuticals, Clinical Operations, Regulations
Promotion
Executive Move
Executive Moves, Promotion
Left Company
Executive Move
Executive Moves, Left Company
Open Position
Open Position
Abpro News & Media
Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72
FDA clearance enables initiation of Abpro’s first clinical-stage solid tumor programAbpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers
IND submitted for ABP-102/CT-P72, a HER2 × CD3 T cell engager, with preclinical studies demonstrating enhanced HER2-high tumor selectivity and a favorable safety profileAbpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives
Continued listing reflects progress on turnaround strategy and pipeline advancement Continued listing reflects progress on turnaround strategy and pipeline advancementAbpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell Engager
BURLINGTON, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Abpro Corporation (Nasdaq: ABP) (“Abpro”) and Celltrion, Inc. (“Celltrion”) today announced that they will present new preclinical data for CT-P72/ABP-102, a tetravalent bispecific antibody targeting HER2 and CD3, at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, being held November 6–10, 2025, at the Gaylord National Resort and Convention Center in National Harbor, Maryland.
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Abpro
Sign Up For FreeTo access detailed company insights
Abpro Corporation is a clinical stage biotechnology company located in Woburn, Massachusetts. The Company's mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro's DiversImmuneTMplatform has been used successfully to generate monoclonal antibody therapies against 300 tr... Read More
